Survival benefits of postoperative radiotherapy in esophageal cancer during the immunotherapy era:a retrospective cohort study based on the SEER database and a single-center registry in China

Qian Zhang, Jia‐Tao Zhang, Jiaqi Gu, X. Zhang, Yuxin Mao, Yingying Zhu, Jin Zhang, Jingyi Wang, Shuyang Chen, Yang Cao, Muhong Wang, Chunbo WangFrontiers in Immunology 2025 · DOI

This study, published in Frontiers in Immunology, investigates whether postoperative radiotherapy (PORT) provides a survival edge for esophageal cancer (EC) patients in the modern era of immunotherapy. While PORT showed no significant benefit for the general patient population, the researchers discovered a significant survival boost when PORT was combined with immunotherapy, suggesting a potent synergistic effect that could redefine treatment for high-risk subgroups.

TL;DR

While postoperative radiotherapy (PORT) does not appear to improve survival for all esophageal cancer patients, it shows a significant synergistic benefit when combined with immunotherapy. This dual-cohort study suggests that for specific high-risk patients, the "immunotherapy + radiation" combo may be the key to overcoming the high recurrence rates seen with surgery alone.

What Problem Does This Paper Address?

Esophageal cancer (EC) remains one of the deadliest malignancies globally, with a particularly high incidence in Asian countries. The current standard of care—neoadjuvant chemoradiation (nCRT) followed by surgery—still leaves many patients facing recurrence rates as high as 31% to 49%.

Since the approval of Immune Checkpoint Inhibitors (ICIs) for EC in 2019, the treatment landscape has shifted dramatically. However, the clinical community has been divided on whether PORT still adds value in this new "immunotherapy era." Does radiation help "prime" the immune system, or is it redundant? This paper seeks to clarify PORT's role by analyzing real-world data from both Western and Eastern patient populations.

Methods

The researchers conducted a retrospective cohort study using two distinct datasets to ensure geographic and histological diversity. To minimize the inherent biases of retrospective data, they employed Propensity Score Matching (PSM) to equilibrate patient characteristics (like age, sex, and tumor stage) between those who received PORT and those who did not.

Survival outcomes were measured using Kaplan-Meier analysis, while the Cox proportional hazards model was used to identify independent risk factors. This allowed the team to move beyond "does it work?" to "for whom does it work?"

Datasets

The study integrated data from 733 total patients across two primary sources:

  • The SEER Database (USA): 407 patients, predominantly featuring Adenocarcinoma (AC) histology.
  • Single-Center Registry (Harbin, China): 326 patients, predominantly featuring Squamous Cell Carcinoma (SCC) histology.

This dual-source approach is vital because EC manifests differently across these populations; SCC is more common in China, while AC is more prevalent in the West.

Key Insights and Ideas

  • The Synergy Hypothesis: The most striking finding was that while PORT alone didn't move the needle for the overall cohort, it significantly improved survival in the immunotherapy subgroup (p=0.044). This supports the idea that radiotherapy can induce "immunogenic cell death," essentially turning the tumor into an in-situ vaccine that enhances the efficacy of immunotherapy.
  • Histology and Sensitivity: The benefit was more pronounced in the Chinese cohort (mostly SCC). SCC is historically more sensitive to radiotherapy and may respond more robustly to the combination of radiation and immune checkpoint inhibitors than Adenocarcinoma.
  • Risk Stratification is Essential: The study identified clear "high-risk" markers where PORT might be most necessary. Patients with advanced pathological stages (ypT3-4), lymph node metastasis (ypN1-3), or R1/R2 resections (where microscopic tumor remains) showed significantly higher survival risks, making them the primary candidates for intensified postoperative therapy.

Key Results

  • Overall Survival (OS): No significant difference was found in the general cohorts (Median OS: 38 months for SEER, 39 months for Chinese cohort).
  • Immunotherapy Subgroup: In the Chinese cohort, the combination of immunotherapy and PORT significantly improved survival (p=0.044).
  • Hazard Ratios (HR): Multivariate analysis revealed massive risk increases for specific groups:
  • Age ≥70: HR = 10.96 (compared to <50 years).
  • Tumor Stage (ypT3-4): HR = 2.12.
  • Lymph Node Status (ypN3): HR = 6.68.
  • Nodal Progression: There was a clear, incremental relationship between the number of positive lymph nodes (ypN1 through ypN3) and the risk of death.

Limitations and Future Work

The authors acknowledge several hurdles:

  1. Retrospective Nature: Despite PSM, retrospective studies cannot fully account for all confounding variables or the "selection bias" of which patients doctors chose for PORT.
  2. Follow-up Time: Because immunotherapy is a relatively recent addition to EC treatment, the follow-up period for that specific subgroup is shorter than for the historical SEER data.
  3. Sample Size: The immunotherapy + PORT subgroup, while significant, remains relatively small.

The Verdict: The authors conclude that while these results are promising, they must be validated through large-scale, prospective randomized controlled trials (RCTs) to confirm the optimal timing and sequencing of PORT and immunotherapy.

Summary updated

Abstract

The collaborative effect of immunotherapy and PORT potentially enhances survival outcomes for patients with EC. However, further prospective research is essential to confirm our results.
BibTeX
@inproceedings{zhang2025survival,
  author = {Qian Zhang and Jia‐Tao Zhang and Jiaqi Gu and X. Zhang and Yuxin Mao and Yingying Zhu and Jin Zhang and Jingyi Wang and Shuyang Chen and Yang Cao and Muhong Wang and Chunbo Wang},
  title = {{Survival benefits of postoperative radiotherapy in esophageal cancer during the immunotherapy era:a retrospective cohort study based on the SEER database and a single-center registry in China}},
  booktitle = {Frontiers in Immunology},
  year = {2025},
  doi = {10.3389/fimmu.2025.1548520},
}
Figure